Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 9:15:1372317.
doi: 10.3389/fphar.2024.1372317. eCollection 2024.

Editorial: Repurposing β-blockers for non-cardiovascular diseases

Ayaz Shahid  1 , Jeffrey Wang  1 , Bradley T Andresen  1 , S R Wayne Chen  2 , Ying Huang  1
Affiliations
Editorial

Editorial: Repurposing β-blockers for non-cardiovascular diseases

Ayaz Shahid et al. Front Pharmacol. .
No abstract available

Keywords: B-blockers; cancer; non-cardiovascular diseases; sepsis; β-adrenergic receptor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Comment on

  • Editorial on the Research Topic Repurposing β-blockers for non-cardiovascular diseases

References

    1. Alaskar A., Abdulraqeb Ali A., Hassan S., Shinwari Z., Alaiya A., von Holzen U., et al. (2023). Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells. Prostate 83 (3), 237–245. 10.1002/pros.24455 - DOI - PMC - PubMed
    1. Beaman E. E., Bonde A. N., Larsen S. M. U., Ozenne B., Lohela T. J., Nedergaard M., et al. (2023). Blood-brain barrier permeable β-blockers linked to lower risk of Alzheimer's disease in hypertension. Brain 146 (3), 1141–1151. 10.1093/brain/awac076 - DOI - PMC - PubMed
    1. Chen S., Tian P., Estau D., Li Z. (2023). Effects of β-blockers on all-cause mortality in patients with diabetes and coronary heart disease: a systematic review and meta-analysis. Front. Cell Dev. Biol. 11, 1076107. 10.3389/fcell.2023.1076107 - DOI - PMC - PubMed
    1. Fjaestad K. Y., Romer A. M. A., Goitea V., Johansen A. Z., Thorseth M. L., Carretta M., et al. (2022). Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment. Oncogene 41 (9), 1364–1375. 10.1038/s41388-021-02170-0 - DOI - PMC - PubMed
    1. Hocht C., Bertera F. M., Del Mauro J. S., Taira C. A. (2014). Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers. Expert Opin. Drug Metab. Toxicol. 10 (4), 525–541. 10.1517/17425255.2014.885951 - DOI - PubMed

Publication types

LinkOut - more resources